Current management of children and young people with heterozygous familial hypercholesterolaemia - HEART UK statement of care.
Children and young people
Familial hypercholesterolaemia
Heterozygous familial hypercholesterolaemia
Lifestyle advice
Statin treatment
Journal
Atherosclerosis
ISSN: 1879-1484
Titre abrégé: Atherosclerosis
Pays: Ireland
ID NLM: 0242543
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
27
06
2019
revised:
08
09
2019
accepted:
12
09
2019
pubmed:
20
9
2019
medline:
4
8
2020
entrez:
20
9
2019
Statut:
ppublish
Résumé
This consensus statement on the management of children and young people with heterozygous familial hypercholesterolaemia (FH) addresses management of paediatric FH in the UK, identified by cascade testing when a parent is diagnosed with FH and for those diagnosed following incidental lipid tests. Lifestyle and dietary advice appropriate for children with FH; suggested low density lipoprotein cholesterol (LDL-C) targets and the most appropriate lipid-lowering therapies to achieve these are discussed in this statement of care. Based on the population prevalence of FH as ~1/250 and the UK paediatric population, there are approximately 50,000 FH children under 18 years. Currently only about 550 of these children and young people have been identified and are under paediatric care.
Identifiants
pubmed: 31536851
pii: S0021-9150(19)31479-0
doi: 10.1016/j.atherosclerosis.2019.09.005
pii:
doi:
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Types de publication
Journal Article
Practice Guideline
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-8Subventions
Organisme : Medical Research Council
ID : G1002158
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG08/008
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Informations de copyright
Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.